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In a clinical setting, where multiple administrations of the ther-
apeutic agent are usually required to improve the therapeutic
outcome, it is crucial to assess the immunogenicity of the admi-
nistered nanoparticles. In this data work, we investigated the
safety proﬁle of the repeated intravenous administration of brain-
targeted stable nucleic acid lipid particles (RVG-9r-targeted
SNALPs). To evaluate local activation of the immune system, we
performed analysis of mouse tissue homogenates and sections
from cerebellum. To investigate peripheral activation of the
immune system, we used serum of mice that were intravenously
injected with RVG-9r-targeted SNALPs. These data are related and
were discussed in the accompanying research article entitled
“Intravenous administration of brain-targeted stable nucleic acid
lipid particles alleviates Machado–Joseph disease neurological
phenotype” (Conceição et al., in press) [1].vier Inc. This is an open access article under the CC BY license
/j.biomaterials.2015.12.021
uroscience and Cell Biology, University of Coimbra, Rua Larga, 3004-504
351 239 853 409.
.pt (L.P. de Almeida).
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(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biology/Neurosciences
ore speciﬁc sub-
ject areaImmunologyype of data Text, ﬁgures with microscopy images and graphs, tables
ow data was
acquiredMicroscope (Zeiss PALM Axiovert 200M), Real-time PCR system (Step One Plus
Real-Time PCR System, Applied Biosystems), Spectrophotometer (Spectramax
Plus 384, Molecular Devices). Results were analyzed using GraphPad Prism
softwareata format Analyzed
xperimental
factorsMice were intravenously injected with brain-targeted stable nucleic acid lipid
particlesxperimental
featuresMouse serum, mouse brain sections and mouse cerebellar homogenates were
analyzed to evaluate the immune responseata source
locationCenter for Neurosciences and Cell Biology, University of Coimbra, Coimbra,
Portugalata accessibility Data is supplied in this articleDValue of the data Provide an insight of the tolerability of brain-targeted SNALPs.
 Evaluate whether intravenous administration of RVG-9r-targeted SNALPs would contribute to
inﬂammation, which could preclude repeated intravenous administration.
 Compare to other data that show the immune response upon administration of siRNA delivery
systems.
 Constitute a support for the future development of non-viral vectors as therapeutic vehicles.1. Data
Nucleic acids are potential activators of the immune system and can stimulate the production of
high levels of inﬂammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-
6) and interferons [2,3]. Another potent inﬂammatory cytokine that is highly produced in the central
nervous system as a response to damage, stress or disease is interleukin-1beta (IL-1β). To investigate
whether intravenous administration of RVG-9r-targeted SNALPs would contribute to inﬂammation,
which could preclude repeated administration, we ﬁrst evaluated the mRNA levels of pro-
inﬂammatory cytokines (IL-1β, IL-6 and TNF-α) and a microglia-related gene (Cebpb) in the cere-
bella of these animals. No signiﬁcant differences were detected in the mRNA levels of these mediators
between HBS-injected mice or mice injected with RVG-9r-targeted SNALPs (Fig. 1A and B).
To evaluate whether repeated intravenous administration of RVG-9r-targeted SNALPs would
activate microglia, we measured Iba-1 immunoreactivity in the cerebellum. When compared to HBS-
injected animals, no signiﬁcant increase in Iba-1 immunoreactivity was detected for the animals
injected with RVG-9r-targeted SNALPs (Fig. 2).
Fig. 2. Repeated intravenous administration of RVG-9r-targeted SNALPs does not elicit local microglial activation. 8 weeks after
starting the treatment, mice were sacriﬁced and Iba-1 staining was evaluated by ﬂuorescence immunohistochemistry. (A–C)
Fluorescence microscopy images of microglia stained with Iba-1 antibody, with a 5 objective. (D) Quantiﬁcation of the Iba-1
immunoreactivity. Values are presented as mean7SEM of n¼5/6. One-way ANOVA analysis of variance combined with
Bonferroni’s post-test was used to compare animals injected with HBS versus siMutAtax3 and siCTR (n.s. p40.05). (E–G)
Fluorescence microscopy images of microglia stained with Iba-1 antibody, with a 20 objective.
Fig. 1. Intravenous administration of RVG-9r-targeted SNALPs does not stimulate the production of pro-inﬂammatory cyto-
kines neither the activation of microglia. (A) mRNA relative levels of pro-inﬂammatory mediators (IL-1β, IL-6 and TNF-α) in the
cerebellum of MJD transgenic mice injected with RVG-9r-targeted SNALPs (black – siCTR, red – siMutAtax3) relatively to
animals injected with HBS (gray). Results were normalized using HPRT housekeeping gene. (B) mRNA relative levels of a
microglia-related gene – Cebpb – in the cerebellum of MJD transgenic mice. Values are presented as mean7SEM of at least
4 independent experiments. One-way ANOVA analysis of variance combined with Bonferroni’s post-test was used for multiple
comparisons (n.s. p40.05).
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incorporating siRNAs and RVG-9r strongly increased the levels of the IL-6 pro-inﬂammatory cytokine
[4], we evaluated whether RVG-9r-targeted SNALPs would transiently increase IL-6 levels. Four hours
Table 1
Intravenous administration of RVG-9r-targeted SNALPs increase IL-6 serum levels. The levels of IL-6 for non-injected wild-type
mice or mice intravenously injected with RVG-9r-targeted liposomes encapsulating siMutAtax3 (siMutAtax3) were measured
by ELISA, 4 h after tail-vein injection. Values are presented as mean7SEM of n¼4. Student’s t-test with Welch’s correction was
used to compare non-injected animals to animals injected with RVG-9r-targeted SNALPs.
Animal Wild Type
Non-injected RVG-9r-Liposomes siMutAtax3
IL-6 levels (pg/mL) 0 39.75712.5*
* po0.05.
Table 2
Repeated intravenous administration of RVG-9r-targeted SNALPs does not increase serum levels of IL-6. The levels of IL-6 for
transgenic mice that were intravenously injected with a saline solution (HBS), RVG-9r-targeted liposomes encapsulating siCTR
(siCTR) and RVG-9r-targeted liposomes encapsulating siMutAtax3 (siMutAtax3) were evaluated by ELISA. A wild-type animal
injected with lipopolysaccharide (LPS) was used as a positive control. Values are presented as mean7SEM of n¼4. One-way
ANOVA analysis of variance combined with Bonferroni’s post-test was used to compare animals injected with HBS versus
siMutAtax3 and siCTR (n.s. p40.05).
Animal Transgenic Wild Type
HBS-injected siCTR siMutAtax3 LPS
IL-6 levels (pg/mL) 1.5371.25 2.971.03 0.8570.85 þ500
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levels of IL-6 (40712.5 pg/mL, Table 1), albeit smaller than what was previously reported [4].
Lastly, we evaluated whether repeated intravenous administration of RVG-9r-targeted SNALPs
(over a 2-months period) would increase the IL-6 levels. When compared to animals injected with a
saline solution, repeated intravenous administration of RVG-9r-targeted SNALPs did not increase
chronically the levels of IL-6 (Table 2).2. Experimental design, materials and methods
2.1. Detection of the cerebellar mRNA levels of inﬂammatory mediators
5-weeks-old C57 BL/6 ataxin-3 [Q69] transgenic mice were intravenously injected on 3 con-
secutive days with 2.5 mg/kg of siRNA (siCTR or siMutAtax3) encapsulated in RVG-9r-targeted lipo-
somes or HEPES-buffered saline solution (HBS). To analyze mutant ataxin-3 levels, mouse cerebella
were harvested 48 h after the third injection. To detect cerebellum mRNA levels, total RNA was
extracted using Qiazol solution (Qiagen) followed by puriﬁcation of the RNA product using the
Nucleospin RNA kit (Macherey-Nagel). cDNA synthesis was performed using the iSCRIPT cDNA
synthesis kit (Bio-Rad). To determine the levels of IL-1β, IL-6 and TNF-α we used 2.5 mL of cDNA
diluted 4 times (for Cebpb cDNA was diluted 10 times) and annealing temperature of 61 °C. qRT-PCR
was performed using SsoAdvanced™ Universal SYBRs Green Supermix (Bio-Rad), in a Step One Plus
Real-Time PCR System (Applied Biosystems). The StepOne Software generated automatically
threshold cycle (Ct) values and the levels of the target gene were calculated using HPRT as house-
keeping gene. The mRNA relative quantiﬁcation was performed with the Pfafﬂ method relatively to
control samples.
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The animals used for this study were the animals that were subjected to behavior assessment in
our accompanying research article [1]. These animals were tail-vein injected with 2.5 mg/kg of siRNAs
(each injection) encapsulated in RVG-9r-targeted liposomes and each mouse received a total of nine
tail-vein injections during the time-course of the experiment.
To determine whether repeated intravenous administration of RVG-9r-targeted SNALPs elicit local
microglial activation, brain tissue was prepared as we described in our accompanying paper [1].
Immunohistochemical procedure was performed as we previously reported [5] with very few
alterations. Brieﬂy, the protocol was initiated with 1 h of blocking and permeabilization in 0.3% Triton
X-100 10% normal goat serum prepared in PBS at room temperature. Sections were then incubated
overnight at 4 °C with the primary antibody rabbit polyclonal anti-Iba1 (1:1000, Wako) that was
prepared in 2% normal goat serum 0.05% Triton X-100 (in PBS). Sections were washed three times
with PBS and incubated with goat-anti-rabbit conjugated to Alexa Fluor 594 (1:250, Molecular
Probes) prepared in 2% normal goat serum (Gibco) for 2 h at room temperature. Nuclei staining was
performed with DAPI, sections were washed three times with PBS and then mounted on gelatinized
slides. After being dried, slides were mounted in Mowiol reagent. Wideﬁeld ﬂuorescence images were
acquired with 5 and 20 objective on a Zeiss PALM Axiovert 200M imaging microscope.
Quantitative analysis of the Iba-1 immunoreactivity was performed by scanning 6 stained-sections
per animal that were distanced 240 mm from each other. Cerebella were imaged using the MosaiX
feature of the Axiovision software (Zeiss) using Zeiss PALM Axiovert 200M microscope with 5
objective. The immunoreactivity indexes were measured through optic density analysis for the entire
cerebellum, using an image-analysis software (Image J software, NIH, USA).
2.3. Quantiﬁcation of IL-6 serum levels by ELISA
For these studies we used mice that were subjected to one or several intravenous administrations
of RVG-9r-targeted SNALPs. For mice that were intravenously injected with RVG-9r-targeted SNALPs
only once, IL-6 serum levels were evaluated 4 h after injection. For the animals that were repeatedly
intravenously injected over a 2-months period (animals that were subjected to behavior assessment),
the levels of serum IL-6 were measured 5 days after the last injection.
Quantiﬁcation of IL-6 serum levels was performed in duplicate, using 50 mL of serum and the
Mouse IL-6 ELISA Kit from Merck Millipore according to the manufacturer’s protocol. The absorbance
was read at 450 nm and 570 nm in a Spectramax Plus 384 spectrophotometer (Molecular Devices),
and the absorbance at 570 nm was subtracted from the absorbance at 450 nm. As a positive control,
one wild-type animal (with approximately 20 g) was intraperitoneally injected with 200 mg of lipo-
polysaccharides (LPS) from Escherichia coli O26:B6.
2.4. Statistical analysis
Data are presented as mean7SEM of at least 4 independent experiments. Student’s t-test or one-
way ANOVA combined with Bonferroni’s post-test were used to determine statistically signiﬁcant
differences of the mean. Statistical differences are presented at probability levels of *po0.05,
**po0.01 and ***po0.001 and considered non-signiﬁcant (n.s.) when p40.05. Calculations were
performed using GraphPad Prism version 5.00 for Windows.Acknowledgments
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